Clinical Trial: A Study of LBP-MARCO and Ruxolitinib in People With Graft-Versus-Host Disease (GVHD)

U.S., Nov. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07913672) titled 'A Study of LBP-MARCO and Ruxolitinib in People With Graft-Versus-Host Disease (GVHD)' on Oct. 28.

Brief Summary: The researchers are doing this study to find out whether the combination of LBP-MARCO (Microbiota Augmentation to Reestablish Commensal Organisms) and ruxolitinib is a safe treatment for people with graft-versus-host disease (GVHD) after receiving a stem cell (allogeneic hematopoietic cell transplantation).

Study Start Date: Oct. 27

Study Type: INTERVENTIONAL

Condition: Transplant Failure or Rejection of Bone Marrow (Graft vs Host Disease, GVHD)

Intervention: DRUG: Ruxolitinib

Ruxolitinib will be initiated concurren...